Short-term clinical effects of periprocedural statin therapy;Effets cliniques à court terme des statines initiées avant une intervention

Presse Medicale

Volumn 42, Issue 3, 2013, Pages 261-268

  Ambrosi, Pierre ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HEART ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PREOPERATIVE TREATMENT; SHORT SURVEY; VASCULAR SURGERY;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY BYPASS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREOPERATIVE CARE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 84875254648     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.05.016     Document Type: Short Survey

References (47)

1. Ambrosi P., Villani P., Habib G., Bouvenot G. Les statines : nouvelles propriétés. Therapie 2003, 58:15-21.
2. Wang C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008, 14:37-44.
3. McGowan M.P. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004, 110:2333-2335. for the Treating to New Target (TNT) study group.
4. Yavin D., Roberts D.J., Tso M., Sutherland G.R., Eliasziw M., Wong J.H. Carotid endarterectomy versus stenting: a meta-analysis of randomized trials. Can J Neur Sci 2011, 38:230-235.
5. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004, 39:967-976.
6. Schouten O., Boersma E., Hoeks S.E., et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009, 361:980-989.
7. Kuhn E.W., Liakopoulos O.J., Choi Y.H., Wahlers T. Current evidence for perioperative statins in cardiac surgery. Ann Thorac Surg 2011, 92:372-379.
8. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006, 114:1455-1461.
9. Song Y.B., On Y.K., KIM J.H., et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008, 156(373):e9-e373. e16.
10. Sun Y., Ji Q., Mei Y., et al. Role of atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. Int Heart J 2011, 52:7-11.
11. Ji Q., Mei Y., Wang X., et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009, 73:2244-2249.
12. Mannacio V.A., Iorio D., De Amicis V., Di Lello F., Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008, 136:1541-1548.
13. Ludman A.J., Hausenloy D.J., Babu G. Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Bas Res Cardiol 2011, 106:1387-1395.
14. Rahimi K., Emberson J., McGale P., et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011, 342:d1250.
15. Morales-Villegas E.C., Di Sciascio G., Briguori C. Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins. Int J Hypertens 2011, 904742.
16. Briguori C., Colombo A., Airoldi F., et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004, 25:1822-1828.
17. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., Di Sciascio G., et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004, 110:674-678.
18. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49:1272-1278.
19. Di Sciascio G., Patti G., Pasceri V., Gaspardone A., Colonna G., Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 2009, 54:558-565.
20. Briguori C., Visconti G., Focaccio A., et al. Novel Approaches for Preventing or Limiting Events (Naples) II Trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009, 54:2157-2163.
21. Veselka J., Zemánek D., Hájek P., et al. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol 2009, 104:630-633.
22. Veselka J, Zemanek D, Tomasov P et al. Impact of high-dose atorvastatin pretreatment on peri-PCI myocardial infarction in patients receiving chronic statin therapy. ESC congress Paris 2011. P2362.
23. Cay S., Cagirci G., Sen N., Balbay Y., Durmaz T., Aydogdu S. Prevention of periprocedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther 2010, 24:41-47.
24. Yun K.H., Jeong M.H., Oh S.K., et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009, 137:246-251.
25. Yu X.L., Zhang H.J., Ren S.D., et al. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coron Artery Dis 2011, 22:87-91.
26. Kim J.S., Kim J., Choi D., et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN-STEMI trial. J Am Coll Cardiol Intv 2010, 3:332-339.
27. Fuji K., Kawasaki D., Oka K., et al. The impact of pravastatin pretreatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol Intv 2011, 4:513-520.
28. Winchester D.E., Wen X., Xie L., Bavry A.A. Evidence of pre-procedural statin therapy. J Am Coll Cardiol 2010, 56:1099-1109.
29. Patti G., Cannon C.P., Murphy S.A., et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention. A collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011, 123:1622-1632.
30. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 2011, 124:e574-e651.
31. Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. Eur Heart J 2010, 31:2501-2555.
32. Wright R.S., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Academy of Family Physicians, Society for cardiovascular angiography and interventions, and the society of thoracic surgeons. J Am Coll Cardiol 2011, 57:e215-e367.
33. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011, 32:1769-1818.
34. Alpert J.S., Thygesen K., Antman E., Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36:959-969.
35. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
36. Ioannidis J.P., Karvouni E., Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003, 42:1406-1411.
37. Kini A., Marmur J.D., Kini S. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course. J Am Coll Cardiol 1999, 34:663-671.
38. Nallamothu B.K., Bates E.R. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 2003, 42:1412-1414.
39. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 287:3215-3222.
40. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
41. Paoletti R., Gotto A.M, Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 2004, 109(23 Suppl. 1):III20-III26.
42. Core Group Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE). Circulation 1997, 96:192-201.
43. Azar R.R., Rinfret S., Théroux P., et al. A randomized placebo-controlled trial to assess the efficacy of anti-inflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000, 21:2026-2032.
44. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007, 297:43-51. APEX AMI Investigators.
45. Atar D., Petzelbauer P., Schwitter J., et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the prevention of myocardial reperfusion injury) trial. J Am Coll Cardiol 2009, 53:720-729.
46. Patti G., Chello M., Gatto L., et al. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Cardiovasc Med (Hagerstown) 2010, 11:795-800.
47. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006, 47:338-341.